Announced details
Research and development of multispecific antibodies, antibody drug discovery, drug discovery support, and joint research
Counterparty to the joint research announced in September 2026. The parties aim to create new antibody drug candidates by combining FRONTEO's AI technology with the company's antibody drug discovery technologies, including DoppeLib™.
The materials state that the company has AI technology. Other information, including its location, representative, capital, year of establishment and securities code, is Not disclosed.
The Westin Miyako Kyoto (Kyoto, Kyoto Prefecture)
This does not guarantee future research and development results or commercialization. The specific amount of the impact on results is Not disclosed.
The company does not address Contract Value / Offering price.
Official website of Antibody Engineering & Therapeutics Asia 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | DoppeLib™, IDD-type business |
| Counterparty | FRONTEO, Inc. |
| Counterparty overview | The materials state that the company has AI technology. Other information, including its location, representative, capital, year of establishment and securities code, is Not disclosed. |
| Relationship with the Company | Counterparty to the joint research announced in September 2026. The parties aim to create new antibody drug candidates by combining FRONTEO's AI technology with the company's antibody drug discovery technologies, including DoppeLib™. |
| Launch date | 20 October 2026 (presentation date) |
| Applicable area | Research and development of multispecific antibodies, antibody drug discovery, drug discovery support, and joint research |
| Location | The Westin Miyako Kyoto (Kyoto, Kyoto Prefecture) |
| Impact on Business Performance | This does not guarantee future research and development results or commercialization. The specific amount of the impact on results is Not disclosed. |
| Source | Official website of Antibody Engineering & Therapeutics Asia 2026 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To introduce investors to the technical features and research examples of DoppeLib™, as well as future business development.